Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/337820
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes |
Autor: | Navarro-Navarro, Paula; Álvarez-Twose, Iván; Pérez-Pons, Alba; Henriques, Ana; Mayado, Andrea; García-Montero, Andrés CSIC ORCID; Sánchez-Muñoz, Laura; González-López, Óscar; Matito, Almudena; Caldas, Carolina; Jara-Acevedo, Maria; Orfao, Alberto CSIC ORCID | Palabras clave: | Basophils Eosinophils KITD816V Mastocytosis MCAS (mast cell activation syndrome) |
Fecha de publicación: | may-2023 | Editor: | John Wiley & Sons | Citación: | Allergy: European Journal of Allergy and Clinical Immunology 78(5): 1347-1359 (2023) | Resumen: | [Background]: Current diagnostic algorithms for systemic mastocytosis (SM) rely on the detection of KITD816V in blood to trigger subsequent bone marrow (BM) investigations. [Methods]: Here, we correlated the KITD816V mutational status of paired blood and BM samples from 368 adults diagnosed with mast cell activation syndrome (MCAS) and mastocytosis and determined the potential utility of investigating KITD816V in genomic DNA from blood-purified myeloid cell populations to increase diagnostic sensitivity. In a subset of 69 patients, we further evaluated the kinetics of the KITD816V cell burden during follow-up and its association with disease outcome. [Results]: Our results showed a high correlation (P < .0001) between the KITD816V mutation burden in blood and BM (74% concordant samples), but with a lower mean of KITD816V-mutated cells in blood (P = .0004) and a high rate of discordant BM+/blood− samples particularly among clonal MCAS (73%) and BM mastocytosis (51%), but also in cutaneous mastocytosis (9%), indolent SM (15%), and well-differentiated variants of indolent SM (7%). Purification of different compartments of blood-derived myeloid cells was done in 28 patients who were BM mast cell (MC)+/blood− for KITD816V, revealing KITD816V-mutated eosinophils (56%), basophils (25%), neutrophils (29%), and/or monocytes (31%) in most (61%) patients. Prognostically, the presence of ≥3.5% KITD816V-mutated cells (P < .0001) and an unstable KITD816V mutation cell burden (P < .0001) in blood and/or BM were both associated with a significantly shortened progression-free survival (PFS). [Conclusions]: These results confirm the high specificity but limited sensitivity of KITD816V analysis in whole blood for the diagnostic screening of SM and other primary MCAS, which might be overcome by assessing the mutation in blood-purified myeloid cell populations. | Versión del editor: | http://dx.doi.org/10.1111/all.15584 | URI: | http://hdl.handle.net/10261/337820 | DOI: | 10.1111/all.15584 | ISSN: | 0105-4538 | E-ISSN: | 1398-9995 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
KITD816V_mutation_Navarro_PV_Art2023.pdf | 6,87 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
8
checked on 25-abr-2024
WEB OF SCIENCETM
Citations
8
checked on 29-feb-2024
Page view(s)
20
checked on 28-abr-2024
Download(s)
24
checked on 28-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons